2 Reasons to Buy Illumina, and 1 Reason to Sell
Illumina (NASDAQ: ILMN) leads the genome sequencing industry with a 90% market share in the U.S. and a 75% share globally. It has been this way for more than a decade, and the company is making investments to build on that advantage. But doing great science doesn't necessarily lead to great stock returns. Here are a couple of reasons why investors might want to pick up shares of Illumina, and one issue that might give them pause.
Image source: Getty Images.
You might expect a company that dominates the genome sequencing market would invest heavily in research and development. You'd be right. But last year, Illumina accelerated the pace and is promising to reveal revolutionary new technology as the payoff.
Source Fool.com
